SCHEMBL28420437

SCHEMBL28420437

CCOC(=O)[C@H](O)Cn1ccc(C#N)n1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
HIF1A Q16665 1/20 0.35
ALDH1A1 P00352 4/20 0.35
MAPT P10636 4/20 0.35
HTT P42858 2/20 0.35
KDM4E B2RXH2 4/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
TDP1 Q9NUW8 1/20 0.33
JMJD6 Q6NYC1 1/20 0.33
ELANE P08246 1/20 0.33
MAPK1 P28482 1/20 0.33
NLRP3 Q96P20 1/20 0.33
HSD17B10 Q99714 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28420438 1.00 GAA (0.36) GAAMEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL23138130 0.90 JMJD6 (0.32) MEN1KMT2ASMN1; SMN2CYP1A2CYP2C9
SCHEMBL23118091 0.81 GABRD (0.34) SMN1; SMN2ALDH1A1
SCHEMBL23118092 0.81 GABRD (0.34) SMN1; SMN2ALDH1A1
SCHEMBL20703040 0.81 THRB (0.45) GAAMEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL23139176 0.73 KMT2A (0.36) GAAMEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL30595468 0.73 KMT2A (0.36) GAAMEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL26091122 0.73 KMT2A (0.36) GAAMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL20703132 0.73 NLRP3 (0.53) GAAMEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL23139017 0.73 NLRP3 (0.53) GAAMEN1KMT2ASMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223263-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NodThera Limited (GB) 2025-07-10 US disclosed
US-12247011-B2 Selective inhibitors of NLRP3 inflammasome NodThera Limited (GB) 2025-03-11 US disclosed
CN-111356680-B Selective inhibitors of NLRP3 inflammasome 诺瑟拉有限公司 2023-11-28 CN disclosed
EP-3661921-B1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NODTHERA LTD (GB) 2023-10-18 EP disclosed
CN-111356680-A Selective inhibitors of NLRP3inflammasome 诺瑟拉有限公司 2020-06-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12247011-B2 Selective inhibitors of NLRP3 inflammasome NLRP3, NOD1, NLRP1 GAA 2634/4885MEN1 2492/4885KMT2A 4593/4885
US-20250223263-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NLRP3, NOD1, NLRP1 GAA 2634/4885MEN1 2492/4885KMT2A 4593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.